Page 10 - CIRN Annual Report 2017
P. 10

immunogenicity in 108 participants; follow-up will be completed in 2017.
                                                   The Pharmacists as Immunizers study is a prospective CTN study of
                                                          on vaccine coverage, compared to control communities, measured
                               was not common and AEFI did not interfere with study completion
                                                                             In preparation for expected clinical studies of a vaccine to prevent
                                                       the effectiveness of targeted patient interventions by pharmacists
                                                                    began in November 2016 and focuses on communities in NS and
                                                                 vaccine reports, and vaccine doses delivered. This 2-year study
                        highest after the first (unblinded) dose. Systemic muscle aches,
                                  (120/121 participants completed the immunizations). Complete
                           drowsiness and nausea were common after both doses. Fever
                                                              using de-identified pharmacy database information, physician
                                           A phase 1 study of a novel CMV vaccine is testing safety and
                                      immunogenicity results are expected in early 2017.

                                                                                  invasive Haemophilus influenzae type a (Hia) disease in Indigenous  communities, we initiated studies to determine burden of disease,  Hia immunoepidemiology, and knowledge, attitudes, beliefs, and  behaviors about Hia disease among Indigenous communities in  Northern Ontario. Engagement with Indigenous communities is a  central focus of this work. The study is just beginning work

                                                                        New Brunswick.

                Clinical Trials Network (CTN)

                               questions in large and specialized groups with a focus on safety,
                                      sites in Vancouver, Calgary, Hamilton, Toronto, Ottawa, Sudbury,
                        The Clinical Trials Network (CTN) is able to conduct rapid
                                  immunogenicity, and mechanisms of immunity. CTN includes
                           clinical trials to address public health-relevant immunization

                                         Montreal, Quebec City, and Halifax.  The network completed a rapid Phase I study of the VSV-EBOV  Ebola vaccine at the Halifax site in 2015-16, following an expedited  grant application and review process during the Ebola outbreak.  This phase 1 study was completed in <6 weeks, demonstrating  CTN’s strong rapid research response capacity.  A second study assessed the need for a Hepatitis B booster dose  in adolescence for jurisdictions with in
   5   6   7   8   9   10   11   12   13   14   15